728 related articles for article (PubMed ID: 28574670)
1. Performance of Aptima and Cobas HPV testing platforms in detecting high-grade cervical dysplasia and cancer.
Ge Y; Christensen P; Luna E; Armylagos D; Schwartz MR; Mody DR
Cancer Cytopathol; 2017 Aug; 125(8):652-657. PubMed ID: 28574670
[TBL] [Abstract][Full Text] [Related]
2. Immediate histopathologic follow-up of cervista and aptima high-risk HPV assays in women with LSIL cytology.
Zhang H; Varma KR; Han M; Matsko J; Zhao C
Cancer Cytopathol; 2018 Aug; 126(8):525-532. PubMed ID: 29797678
[TBL] [Abstract][Full Text] [Related]
3. [HPV E6 and E7 mRNA combined with HPV 16 and 18 or 45 genotyping testing as a means of cervical cancer opportunistic screening].
Wang JJ; Dong J; Deng ZX; Wang PF; Zhang XX; Du Y
Zhonghua Fu Chan Ke Za Zhi; 2019 May; 54(5):301-306. PubMed ID: 31154710
[No Abstract] [Full Text] [Related]
4. Comparison of the diagnostic value of cervical cytology and HPV HR DNA testing for the diagnosis of low-grade and high-grade squamous intraepithelial lesions across different age groups.
Paluszkiewicz A; Pruski D; Iwaniec K; Kędzia W
Ginekol Pol; 2017; 88(3):141-146. PubMed ID: 28397203
[TBL] [Abstract][Full Text] [Related]
5. Aptima Human Papillomavirus E6/E7 mRNA Test Results Strongly Associated With Risk for High-Grade Cervical Lesions in Follow-Up Biopsies.
Ge Y; Christensen P; Luna E; Armylagos D; Xu J; Schwartz MR; Mody DR
J Low Genit Tract Dis; 2018 Jul; 22(3):195-200. PubMed ID: 29543688
[TBL] [Abstract][Full Text] [Related]
6. HPV genotyping and E6/E7 transcript assays for cervical lesion detection in an Asian screening population-Cobas and Aptima HPV tests.
Wong OGW; Tsun OKL; Tsui EY; Chow JNK; Ip PPC; Cheung ANY
J Clin Virol; 2018 Dec; 109():13-18. PubMed ID: 30368218
[TBL] [Abstract][Full Text] [Related]
7. [Relationship between cervical lesions and the type-specific viral load of high risk HPV reflected by the Ct value of Cobas 4800 HPV system].
Duan LF; Du H; Xiao AM; Wang C; Huang X; Zhao MF; Men HJ; Wu RF
Zhonghua Fu Chan Ke Za Zhi; 2019 Jul; 54(7):458-463. PubMed ID: 31365958
[No Abstract] [Full Text] [Related]
8. HPV detection rates and histopathologic follow-up of patients with HSIL cytology in a large academic women's hospital laboratory.
Ashman D; Zhang H; Li J; Austin M; Wang T; Pradhan D; Zhao C
J Am Soc Cytopathol; 2020; 9(6):550-555. PubMed ID: 32475726
[TBL] [Abstract][Full Text] [Related]
9. Comparison of the Clinical Performance of Aptima HPV Assay and the Cobas 4800 Platform in Women with Normal Cytology and Positive High-Risk HPV.
Kir G; Dokmeci Guney D; Seneldir H
Acta Cytol; 2023; 67(4):395-402. PubMed ID: 36977394
[TBL] [Abstract][Full Text] [Related]
10. High-grade squamous intraepithelial lesion cervicovaginal paps with negative high-risk HPV testing, a prospective study with histological follow-up.
Agoff SN; Brockmeyer AD; Barrie AM; Larson J
Diagn Cytopathol; 2023 Aug; 51(8):475-479. PubMed ID: 37086174
[TBL] [Abstract][Full Text] [Related]
11. An automated quantitative DNA image cytometry system detects abnormal cells in cervical cytology with high sensitivity.
Wong OG; Ho MW; Tsun OK; Ng AK; Tsui EY; Chow JN; Ip PP; Cheung AN
Cytopathology; 2018 Jun; 29(3):267-274. PubMed ID: 29578257
[TBL] [Abstract][Full Text] [Related]
12. Aptima HPV messenger RNA testing and histopathologic follow-up in women with HSIL cytology: A study emphasizing additional review of HPV-negative cases.
Li A; Li J; Austin RM; Wang T; Ashman D; Zhang H; Matsko J; Zhao C
Cancer Cytopathol; 2021 Aug; 129(8):622-631. PubMed ID: 33764649
[TBL] [Abstract][Full Text] [Related]
13. p16 Immunohistochemistry is useful in confirming high-grade squamous intraepithelial lesions (HSIL) in women with negative HPV testing.
Zhang G; Yang B; Abdul-Karim FW
Int J Gynecol Pathol; 2015 Mar; 34(2):180-6. PubMed ID: 25675189
[TBL] [Abstract][Full Text] [Related]
14. Correlation of p16INK4a immunoexpression and human papillomavirus (HPV) detected by in-situ hybridization in cervical squamous neoplasia.
Cheah PL; Koh CC; Nazarina AR; Teoh KH; Looi LM
Malays J Pathol; 2016 Apr; 38(1):33-8. PubMed ID: 27126662
[TBL] [Abstract][Full Text] [Related]
15. Cytology and curetting diagnosis of endocervical adenocarcinoma.
Bruehl FK; Dyhdalo KS; Hou Y; Clapacs E; Przybycin CG; Reynolds JP
J Am Soc Cytopathol; 2020; 9(6):556-562. PubMed ID: 32624383
[TBL] [Abstract][Full Text] [Related]
16. Introduction of liquid-based cytology and human papillomavirus testing in cervical cancer screening in Luxembourg.
Latsuzbaia A; Hebette G; Fischer M; Arbyn M; Weyers S; Vielh P; Schmitt F; Mossong J
Diagn Cytopathol; 2017 May; 45(5):384-390. PubMed ID: 28247516
[TBL] [Abstract][Full Text] [Related]
17. Sensitivity of high-risk HPV Hybrid Capture II (hrHPV HC2) test using SurePath(TM) specimens in the prediction of cervical high-grade squamous lesions.
Zhou F; Pulinthanathu R; Elgert P; Cangiarella J; Simsir A
Diagn Cytopathol; 2015 May; 43(5):381-7. PubMed ID: 25546355
[TBL] [Abstract][Full Text] [Related]
18. Human papillomavirus (HPV) testing in the management of women with abnormal Pap smears. Experience of a colposcopy referral clinic.
Ciotti M; Sesti F; Paba P; Benedetto A; Patrizi L; Criscuolo A; Piccione E; Branca M; Syrjänen K; Favalli C
Eur J Gynaecol Oncol; 2004; 25(5):577-84. PubMed ID: 15493169
[TBL] [Abstract][Full Text] [Related]
19. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
[TBL] [Abstract][Full Text] [Related]
20. Three-year risk of high-grade CIN for women aged 30 years or older who undergo baseline Pap cytology and HPV co-screening.
Guo M; Khanna A; Wang J; Dawlett MA; Kologinczak TL; Lyons GR; Bassett RL; Sneige N; Gong Y; Bevers TB
Cancer Cytopathol; 2017 Aug; 125(8):644-651. PubMed ID: 28498639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
